W
WAVEMAN · COMPANY
ZTS · Zoetis Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ZTS

Zoetis Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001555280
CLUSTER · 3 INSIDERSCONGRESS · 2☆ WATCH
INSIDER NET · 180D
$886.4K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
2
FUNDS ADDED · QTR
683
13F, latest reported quarter
REVENUE GROWTH
+2.3%
XBRL, annual
NET MARGIN
28.2%
CONVERSIONS · 180D
5
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$886.4K over 180 days
more than 87% of Pharma & Biotech
CONGRESS
2 members bought in the last year
more than 65% of Pharma & Biotech
FUNDS
683 funds added or opened last quarter
more than 98% of Pharma & Biotech
REVENUE
+2.3% year over year
more than 50% of Pharma & Biotech
MARGIN
28.2% net margin
more than 91% of Pharma & Biotech
BUYBACKS
$1.2B repurchased, FY to 2026-06-30
more than 95% of Pharma & Biotech
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders independently bought a net $886.4K while the stock fell 40% over six months — no planned sales are queued against it.
683 funds added or opened positions in the latest 13F quarter, of 1,435 holders.
2 members of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -49.2%
-49.2%12M
-52%-35%-17%+0%2025-092025-102025-122026-032026-052026-072026-09 2026-02-17 · PECK KRISTIN C sold $1.4M2026-02-17 · PECK KRISTIN C sold $1.2M2026-05-13 · DAMELIO FRANK A bought $501.3K2026-05-11 · MCCALLISTER MICHAEL B bought $233.3K2026-05-13 · Bisaro Paul bought $151.8K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $886.4K bought by insiders over 180 days, 683 funds added last quarter, 2 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Zoetis Inc. insiders bought a net $886.4K of stock across 72 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
DAMELIO FRANK A
Director
BUY
2026-05-13
6,650.0
$501.3K
Bisaro Paul
Director
BUY
2026-05-13
2,000.0
$151.8K
MCCALLISTER MICHAEL B
Director
BUY
2026-05-11
3,000.0
$233.3K
PECK KRISTIN C
Chief Executive Officer
SELL
2026-02-17
10,800.0
$1.4M
PECK KRISTIN C
Chief Executive Officer
SELL
2026-02-17
9,200.0
$1.2M
72 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 67 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
39,430,181.0 sh
$2.8B
VANGUARD CAPITAL MANAGEMENT LLC
26,027,984.0 sh
$1.9B
VANGUARD PORTFOLIO MANAGEMENT LLC
23,860,445.0 sh
$1.7B
STATE STREET CORP
19,667,723.0 sh
$1.4B
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO
15,892,903.0 sh
$1.1B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ProShares Pet Care ETF
$4.5M POSITION · AS OF 2026-02-28
9.8%
VanEck Agribusiness ETF
$77.0M POSITION · AS OF 2026-03-31
6.9%
iMGP Global Select Fund
$3.9M POSITION · AS OF 2026-03-31
5.1%
Eaton Vance Atlanta Capital Focused Growth Fund
$29.9M POSITION · AS OF 2026-03-31
4.6%
iShares U.S. Pharmaceuticals ETF
$45.2M POSITION · AS OF 2026-03-31
4.5%
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$3.2M POSITION · AS OF 2026-03-31
4.4%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Kristin C. Peck
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$19.0M
$2.8M
$4.0M
-20%
+88%
2024
$17.2M
$759.6K
$3.4M
+2%
+48%
2023
$15.2M
$26.4M
$3.0M
+22%
+37%
2022
$14.0M
-$15.7M
$2.9M
-10%
+36%
2021
$13.1M
$33.5M
$4.5M
+48%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122025-122024-122023-12
REVENUE$9.5B$9.3B$8.5B
NET INCOME$2.7B$2.5B$2.3B
EPS (DILUTED)6.025.475.07
OPERATING CASH FLOW$2.9B$3.0B$2.4B
LONG-TERM DEBT$9.0B$5.2B$6.6B
BUYBACKS$3.2B$248.0M$1.9B$1.1B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →